DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20183804

Impact of premature ovarian insufficiency on cardiovascular health

Kavitha Abraham, Vaibhav Londhe, Tunny Sebastian, Thomas Paul, Aruna Kekre

Abstract


Background: The objectives of the study were to identify the causes of premature ovarian insufficiency (POI) and to assess the severity of menopausal symptoms as well as the impact on cardiovascular health in these patients.

Methods: Authors did a cross sectional case control study with 100 cases and 100 age matched controls. Women <40years of age with amenorrhoea >4months and FSH >25mIU/ml were identified with POI. Women <40years with normal cycles were the controls. Causes were identified from medical records and menopausal symptoms were categorized using menopause rating score questionnaire. Hypercholesterolemia (≥200mg/dl), hypoalbuminemia (<3.5g/dl) and high sensitive C reactive protein (HS-CRP ≥3mg/dl) were assessed as the early markers of coronary artery disease. Statistical methods included Chi square test and logistic regression analysis. P value <0.05 was considered significant.

Results: 64% of the patients were between 31-40 years. 66% of them were into menopause for <5 years. The cause was idiopathic in 62%. 91% had no or minimal menopausal symptoms. Hypoalbuminemia (6 versus 1, 95% CI 1.8-2.4, OR 2.1, p=0.01) and hypercholesterolemia (75 versus 51, 95%CI 2.5-3.1, OR 2.8, p= 0.001) were significantly high in cases. HS-CRP was not found to be different between the groups (59 versus 49, OR 1.5, 95%CI 0.8-2.6, p=0.2).

Conclusions: In majority with POI the cause is idiopathic and menopausal symptoms are minimal. Hypoalbuminemia and hypercholesterolemia, markers of coronary artery disease, were significantly elevated in POI. Early screening for these variables within 5 years of menopause would reduce the cardiovascular mortality in these patients.


Keywords


Cardiovascular disease, Hypercholesterolemia, Hypoalbuminemia, Premature ovarian insufficiency

Full Text:

PDF

References


Podfigurna-Stopa A, Czyzyk A, Grymowicz M, Smolarczyk R, Katulski K, Czajkowski K. Premature ovarian insufficiency: the context of long-term effects. J Endocrinol Invest. 2016;39:983-90.

European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI, Webber L, Davies M, Anderson R, Bartlett J, Braat D, et al. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum Reprod Oxf Engl. 2016;31(5):926-37.

Gulhan I, Bozkaya G, Uyar I, Oztekin D, Pamuk BO, Dogan E. Serum lipid levels in women with premature ovarian failure. Menopause 2012;19(11):1231-4.

Singh T, Sharma S, Seetharamiah N. Socio-economic status scales updated for 2017. Int J Res Med Sci. 2017; 5(7):3264-3267.

Maddison R, Ni Mhurchu C, Jiang Y, Vander Hoorn S, Rodgers A, Lawes CMM et al. International Physical Activity Questionnaire (IPAQ) and New Zealand Physical Activity Questionnaire (NZPAQ): A doubly labelled water validation. Int J Behav Nutr Phys. 2007; Act 4:62.

Heinemann LAJ, Potthoff P, Schneider HPG. International versions of the Menopause Rating Scale (MRS). Health Qual Life Outcomes. 2003; 1:28.

Soran H, Adam S, Mohammad JB, Ho JH, Schofield JD, Kwok S, et al. Hypercholesterolaemia - practical information for non-specialists. Arch Med Sci. 2018; 14(1):1-21.

Kim S, McClave SA, Martindale RG, Miller KR, Hurt RT. Hypoalbuminemia and Clinical Outcomes: What is the Mechanism behind the Relationship? Am Surg. 2017; 83(11):1220-7.

Targher G, Bertolini L, Tessari R, Zenari L, Arcaro G. The international diabetes federation definition of the metabolic syndrome independently predicts future cardiovascular events in Type 2 diabetic patients. The valpolicella heart diabetes study. Diabet Med. 2006;23(11):1270-1.

Podigurna-Stopa A, Czyzyk A, Grymowicz M, Smolarczyk R, Katulski K, Czajkowski K, et al. Premature ovarian insufficiency: the context of long-term effects. J Endocrinol Invest. 2016; 39(9):983-90.

Coulam CB, Adamson SC, Annegers JF. Incidence of premature ovarian failure. Obstet Gynecol. 1986;67(4):604-6.

Atsma F, Bartelink M-LEL, Grobbee DE, van der Schouw YT. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause N Y N. 2006;13(2):265-79.

Ross R. Atherosclerosis-an inflammatory disease. N Eng J Med. 1999 Jan;340(2):115-26.

Virdis A, Ghiadoni L, Pinto S, Lombardo M, Petraglia F, Gennazzani A, et al. Mechanisms responsible for endothelial dysfunction associated with acute estrogen deprivation in normotensive women. Circulation. 2000;101(19):2258-63.

Yorgun H, Tokgözoğlu L, Canpolat U, Gürses KM, Bozdağ G, Yapıcı Z, et al. The cardiovascular effects of premature ovarian failure. Int J Cardiol. 2013; 168(1):506-10.

Goldmeier S, De Angelis K, Rabello Casali K, Vilodre C, Consolim-Colombo F, Belló Klein A, et al. Cardiovascular autonomic dysfunction in primary ovarian insufficiency: clinical and experimental evidence. Am J Transl Res. 2013;6(1):91-101.

Ates S, Yesil G, Sevket O, Molla T, Yildiz S. Comparison of metabolic profile and abdominal fat distribution between karyotypically normal women with premature ovarian insufficiency and age matched controls. Maturitas. 2014; 79(3):306-10.

Ebong IA, Watson KE, Goff DC, Bluemke DA, Srikanthan P, Horwich T, et al. Age at menopause and incident heart failure: the Multi-Ethnic Study of Atherosclerosis. Menopause. 2014;21(6):585-91.

Rivera CM, Grossardt BR, Rhodes DJ, Brown RD, Roger VL, Melton LJ, et al. Increased cardiovascular mortality after early bilateral oophorectomy. Menopause N Y N. 2009; 16(1):15-23.

Gierach GL, Pfeiffer RM, Patel DA, Black A, Schairer C, Gill A, et al. Long-term overall and disease-specific mortality associated with benign gynecologic surgery performed at different ages. Menopause 2014; N Y N. 21(6):592-601.

Jefferson DM, Reid LM, Giambrone MA, Shafritz DA, Zern MA. Effects of dexamethasone on albumin and collagen gene expression in primary cultures of adult rat hepatocytes. Hepatology. 1985 Jan 1;5(1):14-20.

Nelson JJ, Liao D, Sharrett AR, Folsom AR, Chambless LE, Shahar E, et al. Serum albumin level as a predictor of incident coronary heart disease: the atherosclerosis risk in communities (ARIC) study. Am J Epidemiol. 2000 Mar 1;151(5):468-77.

Djoussé L, Rothman KJ, Cupples LA, Levy D, Ellison RC. Serum albumin and risk of myocardial infarction and all-cause mortality in the Framingham Offspring Study. Circulation. 2002; 106(23):2919-24.

Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA. 1998;279(18):1477-82.

Luoma PV, Näyhä S, Sikkilä K, Hassi J. High serum alpha-tocopherol, albumin, selenium and cholesterol, and low mortality from coronary heart disease in northern Finland. J Intern Med. 1995; 237(1):49-54.

Schnatz PF. The 2010 North American Menopause Society position statement: Updates on screening, prevention and management of postmenopausal osteoporosis. Connecticut Med. 2011 Sep;75(8):485-7.

Ahmed SH, Kharroubi W, Kaoubaa N, Zarrouk A, Batbout F, Gamra H, et al. Correlation of trans fatty acids with the severity of coronary artery disease lesions. Lipids in health and disease. 2018 Dec;17(1):52.